
New findings on spinal muscular atrophy
Researchers investigate the impact on the immune system.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Researchers investigate the impact on the immune system.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Chuprikova L, Chong L, Ruff S, Seitz S, Lauber C
Hartmann O, Preusse M, Heroven A, Felgner S, Gür M, Kordes A, Wolff Bengtsen V, Roghanian M, Zhao X, Müsken M, Gomez N, Häussler S
Frommeyer Y, Sun J, Wu J, Kennepohl B, Witte J, Gomez N, Battermann J, Becker L, Cetraro P, Verstraten R, Tomasch J, Pich A, Depledge D, Dedon P, Häussler S
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
The project is developing methods to specifically transport antibiotics into cells such as alveolar macrophages, which are important in Mycobacterium tuberculosis infections. The aim is to overcome resistance and reduce side effects.
The project is researching how the effect of monoclonal antibodies can be improved. These antibodies are already being used successfully against viruses. The aim is to optimize the so-called Fc effector functions in order to fight infections even more effectively.
Studies in the cell culture model show that only a few disinfectants are effective against HEV, which provides important information on hygiene measures for HEV infections. We are also working together to test vaccines for pigs as HEV reservoirs.
There are currently no events.

